Peritoneal Cancer Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

PRESS RELEASE
Published March 16, 2023

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 55+ key pharma and biotech companies are working on 55+ pipeline drugs in the Peritoneal Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Peritoneal Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Peritoneal Cancer Market.

The Peritoneal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Peritoneal Cancer Pipeline Analysis
The report provides insights into:

– The report provides detailed insights about emerging therapies for the treatment of Peritoneal Cancer and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peritoneal Cancer Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Peritoneal Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –

– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

– Oral
– Parenteral
– Intravenous
– Subcutaneous
– Topical

Molecule Type
Products have been categorized under various Molecule types, such as

– Monoclonal Antibody
– Peptides
– Polymer
– Small molecule
– Gene therapy

Peritoneal Cancer Therapeutics Landscape

Several major pharma and biotech giants are developing therapies for Peritoneal Cancer. Currently, ImmunoGen is leading the therapeutics market with its Peritoneal Cancer drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Peritoneal Cancer Therapeutics Market Include:

– AbbVie
– Astex Pharmaceuticals, Inc.
– ImmunoVaccine Technologies, Inc. (IMV Inc.)
– Merck & Co
– Novartis Pharmaceuticals
– Pfizer
And Many Others

Peritoneal Cancer Emerging and Marketed Drugs Covered in the Report Include:

– Mirvetuximab soravtansine: ImmunoGen
– Pembrolizumab: Merck & Co
– PF-06873600: Pfizer
And Many More

Explore More About the Emerging Drugs and Key Companies: Peritoneal Cancer Pipeline Development Activities

Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Peritoneal Cancer Current Treatment Patterns
4. Peritoneal Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Peritoneal Cancer Late-Stage Products (Phase-III)
7. Peritoneal Cancer Mid-Stage Products (Phase-II)
8. Peritoneal Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Peritoneal Cancer Discontinued Products
13. Peritoneal Cancer Product Profiles
14. Key Companies in the Peritoneal Cancer Market
15. Key Products in the Peritoneal Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Peritoneal Cancer Unmet Needs
18. Peritoneal Cancer Future Perspectives
19. Peritoneal Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Peritoneal Cancer Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Newsmantraa